https://www.yiliao.com/index.php?action=history&feed=atom&title=Zynlonta
Zynlonta - 版本历史
2026-04-18T18:21:44Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Zynlonta&diff=314030&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-12T03:28:46Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Loncastuximab]]</strong>（全称：<strong>[[Loncastuximab Tesirine]]</strong>，通用名为<strong>[[奥隆司妥单抗]]</strong>），商品名为 <strong>[[Zynlonta]]</strong>，研发代码为 <strong>[[ADCT-402]]</strong>，是由 <strong>[[ADC Therapeutics]]</strong> 研发的一种针对 <strong>[[CD19]]</strong> 靶点的首创 <strong>[[抗体偶联药物]]</strong>（<strong>[[ADC]]</strong>）。该药物由人源化 IgG1 抗体与强效 DNA 跨链结合剂 <strong>[[PBD]]</strong>（吡咯并苯二氮卓）二聚体偶联而成。<strong>[[Loncastuximab]]</strong> 主要用于治疗 <strong>[[复发或难治性大B细胞淋巴瘤]]</strong>（<strong>[[R/R DLBCL]]</strong>），是全球首个获批用于该适应症的针对 <strong>[[CD19]]</strong> 的 <strong>[[ADC]]</strong>。作为一种现货型疗法，它为既往接受过多种方案（包括 <strong>[[CAR-T]]</strong> 细胞疗法）后进展的淋巴瘤患者提供了关键的补救治疗手段。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Zynlonta (奥隆司妥单抗)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Loncastuximab Tesirine · ADCT-402</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Zynlonta: CD19-directed ADC with PBD dimer payload</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px;">核心靶点：<strong>[[CD19]]</strong></div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%; font-weight: normal;"><strong>[[Entrez]]</strong>ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">930 (<strong>[[CD19]]</strong>)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;"><strong>[[HGNC]]</strong>ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1633</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">药物荷载</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[SG3199]]</strong> (PBD Dimer)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">平均DAR</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2.3</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">静脉滴注 (IV)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[ADC Therapeutics]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; font-weight: normal;">审批状态</th><br />
<td style="padding: 12px; color: #16a34a;">FDA 已获批</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：PBD 介导的 DNA 永久闭锁</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[Loncastuximab]]</strong> 的作用原理结合了抗体的精准定位能力与 <strong>[[PBD]]</strong> 毒素的极高细胞毒性：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">靶向识别：药物的人源化抗体部分特异性结合 B 细胞表面的 <strong>[[CD19]]</strong> 抗原。该靶点在弥漫大 B 细胞淋巴瘤等病灶中表达非常稳定。</li><br />
<li style="margin-bottom: 12px;">毒素释放：<strong>[[ADC]]</strong> 复合物被内吞进入溶酶体后，通过蛋白酶切割释放出活性载荷 <strong>[[SG3199]]</strong>。</li><br />
<li style="margin-bottom: 12px;">DNA 交联：<strong>[[PBD]]</strong>（吡咯并苯二氮卓）二聚体通过结合 DNA 小沟，在两条链之间形成不可逆的共价交联，彻底阻断 DNA 复制和转录，导致肿瘤细胞凋亡。</li><br />
<li style="margin-bottom: 12px;">细胞周期无关性：由于直接作用于 DNA 结构，该药不仅杀伤分裂期细胞，对静止期的肿瘤克隆亦有显著清除作用。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究与获益矩阵 (LOTIS-2)</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%; font-weight: bold;">研究维度</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; font-weight: bold;"><strong>[[LOTIS-2]]</strong> 研究结果</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; font-weight: bold;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">客观缓解率 (ORR)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">48.3%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在多线复发难治患者中展现了极高的缓解率。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">完全缓解率 (CR)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">24.8%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约四分之一的重症患者实现了病灶完全消失。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[CAR-T]]</strong> 经治获益</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">ORR 约 46%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">证明了其对 <strong>[[CAR-T]]</strong> 失败人群的有效挽救能力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">安全性表现</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;" colspan="2;">常见中性粒细胞减少、<strong>[[GGT]]</strong> 升高及特征性的 <strong>[[水肿]]</strong> 风险。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：毒性防控与现货化管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
临床应用 <strong>[[Loncastuximab]]</strong> 时，需重点关注其独特的安全性图谱与用药便利性：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">即买即用：相比制备周期较长的 <strong>[[CAR-T]]</strong> 疗法，该药作为现货药物，可为进展迅速的患者提供即时治疗。</li><br />
<li style="margin-bottom: 12px;"><strong>[[浆膜腔积液]]</strong> 防治：载荷 <strong>[[PBD]]</strong> 可能引发胸水或腹水。指南建议给药前一天开始连续三天口服 <strong>[[地塞米松]]</strong>（4mg BID）进行预防。</li><br />
<li style="margin-bottom: 12px;">皮肤光敏性管理：由于 <strong>[[PBD]]</strong> 载荷的特性，患者在治疗期间应采取严格防晒措施，避免紫外线引发的皮肤红肿。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CD19]]</strong>：B 细胞恶性肿瘤最广泛的免疫靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[PBD]]</strong> 二聚体：诱导 DNA 跨链共价交联的强效 <strong>[[ADC]]</strong> 毒素载荷。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DLBCL]]</strong>：弥漫大 B 细胞淋巴瘤，该药的核心适应症。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ADC Therapeutics]]</strong>：专注于 <strong>[[PBD]]</strong> 平台研发的创新生物制药公司。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] Caimi PF, et al. (2021). Loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <strong>[[The Lancet Oncology]]</strong>.<br />
<br><span style="color: #475569;">[权威点评]：该研究确立了其作为 <strong>[[DLBCL]]</strong> 挽救治疗的核心价值。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] Kahl BS, et al. (2022). Loncastuximab Tesirine: A New Treatment Paradigm for B-Cell Lymphomas. <strong>[[Blood Reviews]]</strong>.[Academic Review]<br />
<br><span style="color: #475569;">[学术点评]：解析了 <strong>[[PBD]]</strong> 载荷在克服传统化疗耐药方面的分子学优势。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Loncastuximab (Zynlonta) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[CD19]]</strong>•<strong>[[PBD]]</strong>•<strong>[[DNA交联]]</strong>•<strong>[[IgG1]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类竞品</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[Polatuzumab Vedotin]]</strong>•<strong>[[Tafasitamab]]</strong>•<strong>[[Axi-cel]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键实体</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[ADC Therapeutics]]</strong>•<strong>[[FDA]]</strong>•<strong>[[NCCN指南]]</strong>•<strong>[[海正药业]]</strong></td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">联合 <strong>[[利妥昔单抗]]</strong> 一线应用•针对 <strong>[[滤泡性淋巴瘤]]</strong> 扩展•降低水肿风险的剂量优化•<strong>[[CAR-T]]</strong> 进展后的序贯方案</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80